These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 18001404

  • 21. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
    Kim N, Park SH, Seo GS, Lee SW, Kim JW, Lee KJ, Shin WC, Kim TN, Park MI, Park JJ, Hong SJ, Shim KN, Kim SW, Shin YW, Chang YW, Chun HJ, Lee OJ, Jeon WJ, Park CG, Cho CM, Park CH, Won SY, Lee GH, Park KS, Shin JE, Kim HU, Park JY, Chae HS, Song GA, Kim JG, Yoon BC, Seol S, Jung HC, Chung IS.
    Helicobacter; 2008 Dec; 13(6):542-9. PubMed ID: 19166420
    [Abstract] [Full Text] [Related]

  • 22. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, Lui YH, Lam KN, Choi CH, Leung EM.
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [Abstract] [Full Text] [Related]

  • 23. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [Abstract] [Full Text] [Related]

  • 24. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH.
    BMC Gastroenterol; 2013 Sep 19; 13():138. PubMed ID: 24050512
    [Abstract] [Full Text] [Related]

  • 25. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
    Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel Huinink J.
    Am J Gastroenterol; 1996 Jan 19; 91(1):93-7. PubMed ID: 8561152
    [Abstract] [Full Text] [Related]

  • 26. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
    Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ, Lo GH, Wu JY, Wu IC, Wang WM, Tseng HH.
    Eur J Clin Invest; 2006 Nov 19; 36(11):803-9. PubMed ID: 17032348
    [Abstract] [Full Text] [Related]

  • 27. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain.
    Schwarzer A, Urruzuno P, Iwańczak B, Martínez-Gómez MZ, Kalach N, Roma-Giannikou E, Liptay S, Bontem P, Buderus S, Wenzl TG, Koletzko S, ESPGHAN Working Group on Helicobacter pylori Infection.
    J Pediatr Gastroenterol Nutr; 2011 Apr 19; 52(4):424-8. PubMed ID: 21407111
    [Abstract] [Full Text] [Related]

  • 28. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
    Chung KH, Lee DH, Jin E, Cho Y, Seo JY, Kim N, Jeong SH, Kim JW, Hwang JH, Shin CM.
    Gut Liver; 2014 Nov 19; 8(6):605-11. PubMed ID: 25368747
    [Abstract] [Full Text] [Related]

  • 29. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
    Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, Seto WK, Wong SY, Chan CK, Gu Q, Tong TS, Cheung TK, Chu KM, Wong BC.
    Helicobacter; 2009 Dec 19; 14(6):505-11. PubMed ID: 19889067
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N.
    World J Gastroenterol; 2015 May 14; 21(18):5568-74. PubMed ID: 25987781
    [Abstract] [Full Text] [Related]

  • 31. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N.
    World J Gastroenterol; 2015 Jul 14; 21(26):8132-9. PubMed ID: 26185386
    [Abstract] [Full Text] [Related]

  • 32. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.
    J Gastroenterol Hepatol; 2005 Apr 14; 20(4):637-42. PubMed ID: 15836716
    [Abstract] [Full Text] [Related]

  • 33. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
    Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A.
    Am J Gastroenterol; 2001 Jan 14; 96(1):58-62. PubMed ID: 11197288
    [Abstract] [Full Text] [Related]

  • 34. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L, Estrada R, Trujillo M, Emami S.
    Am J Gastroenterol; 1997 Dec 14; 92(12):2213-5. PubMed ID: 9399755
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Nam RH, Suh JH, Lee JW, Lee DH.
    Scand J Gastroenterol; 2016 Mar 14; 51(3):270-6. PubMed ID: 26452405
    [Abstract] [Full Text] [Related]

  • 36. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
    Antos D, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdörffer E.
    Helicobacter; 2006 Feb 14; 11(1):39-45. PubMed ID: 16423088
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection.
    Hsu CC, Chen JJ, Hu TH, Lu SN, Changchien CS.
    Hepatogastroenterology; 2005 Feb 14; 52(65):1617-21. PubMed ID: 16201128
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.